JULY 10, 2026 AT 03:23 PM

US FDA approves PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer regardless of cisplatin eligibility

ByNewsquawk Staff

Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.

#FDA#EU SESSION#US SESSION#US EQUITIES

© 2026 Newsquawk. All rights reserved.